| Literature DB >> 35744255 |
Alimjon D Matchanov1,2, Rakhmat S Esanov1, Tobias Renkawitz3, Azamjon B Soliev4, Elke Kunisch3, Isabel Gonzalo de Juan5, Fabian Westhauser3, Dilshat U Tulyaganov4.
Abstract
Medical nutrients obtained from plants have been used in traditional medicine since ancient times, owning to the protective and therapeutic properties of plant extracts and products. Glycyrrhizic acid is one of those that, apart from its therapeutic effect, may contribute to stronger bones, inhibiting bone resorption and improving the bone structure and biomechanical strength. In the present study, we investigated the effect of a bioactive glass (BG) addition to the structure-property relationships of supramolecular assemblies formed by glycyrrhizic acid (GA) and its monoammonium salt (MSGA). FTIR spectra of supramolecular assemblies evidenced an interaction between BG components and hydroxyl groups of MSGA and GA. Moreover, it was revealed that BG components may interact and bond to the carboxyl groups of MSGA. In order to assess their biological effects, BG, MSGA, and their supramolecular assemblies were introduced to a culture of human bone-marrow-derived mesenchymal stromal cells (BMSCs). Both the BG and MSGA had positive influence on BMSC growth, viability, and osteogenic differentiation-these positive effects were most pronounced when BG1d-BG and MSGA were introduced together into cell culture in the form of MSGA:BG assemblies. In conclusion, MSGA:BG assemblies revealed a promising potential as a candidate material intended for application in bone defect reconstruction and bone tissue engineering approaches.Entities:
Keywords: bioactive glasses; bone tissue engineering; glycyrrhizic acid; supramolecular assemblies
Year: 2022 PMID: 35744255 PMCID: PMC9230998 DOI: 10.3390/ma15124197
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.748
Figure 1Structure of monoammonium salt of glycyrrhizic acid (MSGA): the right upper part is hydrophobic (triterpene part), and the left is hydrophilic (carbohydrate part).
Figure 2Photographs of supramolecular assemblies of bioactive glass with MSGA: (a) in powder form, from the right to the left samples MSGA:BG 50:1; MSGA:BG 20:1; MSGA:BG 10:1 and the leftmost is MSGA; (b) in gel form, from the left to the right samples MSGA:BG 20:1 and MSGA:BG 50:1.
pH of as-prepared 0.1 wt.% solutions.
| No. | Supramolecular Assemblies | pH |
|---|---|---|
| 1 | GA:BG 10:1 | 3.29 |
| 2 | GA:BG 20:1 | 3.23 |
| 3 | GA:BG 50:1 | 2.99 |
| 4 | MSGA:BG 10:1 | 4.33 |
| 5 | MSGA:BG 20:1 | 3.92 |
| 6 | MSGA:BG 50:1 | 3.43 |
Figure 3FTIR spectra of (a) MSGA and MSGA:BG complexes, (b) GA and GA:BG complexes.
Figure 4UV spectra of (a) MSGA:BG complexes and (b) GA:BG complexes: lines in red—MSGA/GA:BG 10:1, lines in green—MSGA/GA:BG 20:1, lines in black—MSGA/GA:BG 50:1.
Figure 5Impact of supramolecular complexes of MSGA:BG on cell number, viability, and ALP activity of BMSCs. Bars show mean ± SD. p < 0.05 Mann–Whitney U test control (+), MSGA (°), or BG (^) group vs. MSGA:BG complex-treated groups, as indicated by brackets; * p < 0.5 Mann–Whitney U test between the MSGA:BG complexes treated groups as indicated by brackets. The grey box in (b) shows the range of 70% (threshold) to 100% viability. FI: fluorescence intensity.
Figure 6Proposed scheme of interaction between MSGA and BG’s structural units in the as-prepared hybrids.